Regeneron announces analyses from Phase 3 C-Post trial

Regeneron (REGN) Pharmaceuticals announced detailed analyses from the Phase 3 C-POST trial, which evaluated PD-1 inhibitor Libtayo in patients with high-risk cutaneous squamous cell carcinoma, CSCC, after surgery. The results, shared during an oral session at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting and simultaneously published in the New England Journal of Medicine, NEJM, include additional data for the primary endpoint of disease-free survival, DFS, and the first presentation of key secondary endpoint outcomes. With a median duration of follow-up of 24 months, efficacy results for Libtayo compared to placebo, were as follows: 68% reduction in the risk of disease recurrence or death, with median DFS not reached for Libtayo-treated patients; At two years, DFS was 87% with Libtayo versus 64% with placebo; 80% reduction in the risk of locoregional recurrence; 65% reduction in the risk of distant recurrence